Showing results (31-40 of 4,509) with videos related to

Sort By:
Pageof 451
Future Oncology (London, England)|June 1, 2022
En bloc resection of bladder tumors: challenges and unmet needs in 2022Evangelos N Symeonidis, Ka-Lun Lo, Ka-Lun Chui, et al.
Future Oncology (London, England)|June 22, 2022
Prognosis of patients with poorly differentiated gastric neuroendocrine neoplasms: a multi-center study in ChinaYanling Xu, Lijun Yan, Tiaotiao Chen, et al.
Future Oncology (London, England)|June 22, 2022
Potential value of tumor stiffness and sE-cadherin in predicting the response to neoadjuvant therapy in HER2-positive breast cancersWeixia Zhou, Meng Wu, Hongxia Lin, et al.
Future Oncology (London, England)|July 7, 2022
GOBLET: a phase I/II study of pelareorep and atezolizumab +/- chemo in advanced or metastatic gastrointestinal cancersMaike Collienne, Houra Loghmani, Thomas Charles Heineman, et al.
Future Oncology (London, England)|June 10, 2022
Application and prospect of single-cell sequencing in cancer metastasisYue Zheng, Xiaofeng Yang
Future Oncology (London, England)|June 27, 2022
Methylated ZNF582 as a triage marker for occult cervical cancer and advanced cervical intraepithelial neoplasiaYuehui Su, Yujie Tang, Ting Zhang, et al.
Future Oncology (London, England)|June 20, 2022
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapyEmma Zattarin, Sara Manglaviti, Giulia Apollonio, et al.
Future Oncology (London, England)|June 20, 2022
Changing the landscape of European School of Oncology-European Society for Medical Oncology masterclasses in clinical oncology during the COVID-19 pandemicNicholas Pavlidis, Fedro A Peccatori, Alexandru Eniu, et al.
Future Oncology (London, England)|October 12, 2021
Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?Amer M Zeidan, Tehseen Salimi, Robert S Epstein
Future Oncology (London, England)|October 12, 2021
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPCOliver Sartor, Daniel George, Bertrand Tombal, et al.
Pageof 451